About Janux Therapeutics
Janux Therapeutics (NASDAQ:JANX) specializes in the development of next-generation therapeutics aimed at enhancing the efficacy of cancer treatments. Their focus is on creating innovative drugs that provide targeted treatment options for patients suffering from various types of cancer. Through their proprietary Tumor Activated T Cell Engager (TRACTr) platform, Janux is developing a pipeline of products designed to activate the body’s immune system specifically within the tumor microenvironment. This approach aims to minimize side effects while maximizing therapeutic impact. The company’s objectives include advancing these cutting-edge therapies through clinical trials to demonstrate safety and efficacy, with the ultimate goal of improving patient outcomes in the oncology field.
Snapshot
Operations
Products and/or services of Janux Therapeutics
- Tumor Activated T Cell Engager (TRACTr) platform, developing next-gen immunotherapies for cancer treatment.
- Tumor Activated BiTE (TAC BiTE) programs, designed for solid tumors with enhanced selectivity and minimal off-target effects.
- PSMA-TRACTr program, focusing on prostate cancer, leveraging PSMA targeting for precise therapy.
- EGFR-TRACTr initiative, aimed at treating EGFR-positive solid tumors, including non-small cell lung cancer.
- TROP2-TRACTr project, developed for TROP2-expressing solid tumors, combining targeted therapy and immune activation.
Janux Therapeutics executive team
- Dr. David Alan Campbell Ph.D.President, CEO & Director
- Dr. Thomas Diraimondo Ph.D.Chief Scientific Officer
- Mr. Matt WhitmireVice President of Finance
- Ms. Maria DobekPrincipal Accounting Officer & VP of Accounting
- Mr. Charles M. WinterChief Technical Officer
- Mr. James PenningtonGeneral Counsel & Corporate Secretary
- Ms. Janeen DoyleChief Corporate & Business Development Officer
- Dr. William Y. Go M.D., Ph.D.Chief Medical Officer